Skip to main content
TipRanks
Go Ultimate75% OFF

Fennec Pharmaceuticals (RV41) Q3 2026 Earnings Report

0 Followers

DE:RV41 Q3 2026 EPS Results

Actual EPS
EUR 0.11
Consensus EPS
EUR 0.09
Beat/Miss
Beat by +EUR 0.02
One Year Ago EPS
-EUR 0.02

DE:RV41 Q3 2026 Revenue Results

Actual Revenue
EUR 17.83M
Expected Revenue
EUR 17.16M
Beat/Miss
Beat by +EUR 673.07K
YoY Revenue Growth
+57.34%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/12/2026
Time
Before Open
Conference Call
Thursday, November 12, 2026
DE:RV41 Upcoming Earnings

Fennec Pharmaceuticals's next earnings date is estimated for March 30, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:RV41 Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 12, 2026|% Change Since:23.56%|
Earnings Call Sentiment|Positive

The call was strongly positive, characterized by record revenue, double-digit demand growth, rising enrollments and infusions, improving adherence trends, expanding commercial reach, encouraging clinical evidence, record EBITDA and cash generation, and strong fourth-quarter visibility. The main challenges were higher operating expenses from planned commercial investments, the timing of conversion from enrollment to infusion and revenue, limited immediate revenue contribution from recent formulary wins, uncertainty around adult NCCN timing, and the potential length of the Japan market-access process.

Company Guidance

Management said the productivity curve will continue to increase through the fourth quarter and through, into 2027, while commercial demand continued to grow at a double digit rate in the third quarter, patient enrollments in Fennec HEARS increased 23%, and infusions were up 58% compared to the second quarter of 2026. For the fourth quarter, management expects cash OpEx to be the lowest of the year, coming off Q3 levels of under $13 million, with full-year cash OpEx in the low fifties; it also cited strong visibility into the fourth quarter from the largest number of patients planned infusions, and planned vials carried over from the third quarter and a strong October. Management said PEDMARK has the potential to deliver continued sustainable growth, with the potential for further margin expansion as revenues grow, and described the fourth quarter carryover as 1 of the most significant carryovers in from quarter to quarter that we have ever seen for the product.

  • Record Quarterly Revenue GrowthThird-quarter 2026 net product sales were $19.4 million, compared with $12.5 million in the third quarter of 2025, representing an increase of approximately 56% year over year. Management described the quarter as the best commercial quarter in Fennec's history.
  • Eighth Consecutive Quarter of GrowthManagement reported that the third quarter marked the company's eighth consecutive quarter of growth, reinforcing the stated strength and consistency of its commercial execution.
  • Strong PEDMARK Demand and Patient Services MetricsCommercial demand continued to grow at a double-digit rate in the third quarter compared with the prior quarter. Fennec HEARS patient enrollments increased 23%, while infusions reached a record level, up 58% compared with the second quarter of 2026.
  • Record AYA EnrollmentFennec achieved a record level of adolescent and young adult enrollment in Fennec HEARS during the third quarter, supported by the NCCN 2A recommendation for PEDMARK use in AYA patients.
  • Project Ignite Productivity GainsThe company reported benefits from Project Ignite, its strategic expansion of the sales organization launched in the first quarter of 2026. The initiative added 14 territories and 4 frontline managers, and after two full quarters in the field, the new territory managers were delivering productivity gains and enabling more frequent engagement with health care professionals.
  • Expansion Across Community and Academic AccountsFennec reported strong uptake among community oncologists while continuing to accelerate adoption at academic centers. Management said it was seeing traction in both care models and had added multiple new community accounts while expanding utilization within existing accounts.
  • Actionable GPO and Diagnosis-Code DataThe company expanded partnerships with community practice aggregators to access tumor-specific data and diagnosis codes for AYA patients. In the third quarter, this became an internal alert program that enabled Fennec to target providers with active patients who could be appropriate for PEDMARK, supporting new account additions and expanded utilization.
  • Major Academic-Center Formulary WinFennec secured a formulary win with a very large Midwestern academic center and its home infusion service. The inclusion enables physicians across the center to prescribe PEDMARK and opens the opportunity to reach potentially hundreds of additional patients at that institution.
  • Expanded Customer-Facing Commercial ReachFollowing the territory expansion, Fennec increased its target universe from approximately 1,300 physicians and accounts to approximately 5,000 targets. Management said large-institution formulary wins can provide access to multiple targets within the same institution.
  • Improving Patient Adherence and ContinuationManagement reported that patient adherence and continuation trends were improving each quarter, with programs and learnings helping keep patients on therapy and lower discontinuation. The typical patient journey can range from 4 to 6 months.
  • Positive Investigator-Initiated Trial ResultsAt the SIOP Annual Meeting, Fennec presented oral results from the investigator-initiated phase 2 STS-J01 trial in Japan. The data demonstrated significant hearing protection and provided clinical context regarding antitumor activity with delayed PEDMARK administration.
  • Growing Evidence Base in Adult and Metastatic PopulationsFennec said its strategy of partnering with leading academic institutions was beginning to produce results, with additional data forthcoming in adult and metastatic patient populations. City of Hope plans to present interim data in early January from a study of PEDMARK in adult men with stage 2 and 3 metastatic testicular germ cell tumors, along with real-world feasibility and observed toxicity findings from Fennec HEARS data.
  • Significant Testicular-Cancer OpportunityTesticular cancer patients account for a little north of half of Fennec's business today. Management said the population has substantial cisplatin exposure, that the company has made good inroads, and that it was only scratching the surface of the opportunity.
  • Record Profitability and Cash GenerationThird-quarter non-GAAP adjusted EBITDA was approximately $5.8 million, or 30% of net product sales, compared with $2.0 million, or 16% of sales, in the comparable quarter a year ago and $2.8 million, or 16% of sales, in the second quarter. Fennec generated nearly $7 million in cash from operations, a company record.
  • Positive EPS and Strong Balance SheetThird-quarter EPS was $0.12 per share, compared with a loss of $0.02 per share in the comparable quarter a year ago. Cash and cash equivalents were $48.7 million as of September 30, 2026, or approximately $1.40 per share, with no debt.
  • Operating Leverage and Fourth-Quarter VisibilityManagement said EBITDA grew by $3 million on revenue growth of $2.3 million, reflecting capital efficiency and a predominantly fixed cost base. The company entered the fourth quarter with its largest number of carried-over planned patients, infusions, and vials, supported by strong October performance and stated visibility into fourth-quarter strength.
  • Active Japan Licensing DiscussionsFennec said it remained actively engaged in licensing discussions in Japan, with potential companies attending a pediatric hematology-oncology meeting in Yokohama and the company's chief medical officer participating in the discussions.

DE:RV41 Earnings History

DE:RV41 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 30, 20272026 (Q4)0.15--0.15――
Nov 12, 20262026 (Q3)0.090.11-0.02700.00% (+0.13)
Aug 11, 20262026 (Q2)0.020.05-0.1145.45% (+0.15)
May 14, 20262026 (Q1)-0.040.01-0.04125.00% (+0.05)
Mar 24, 20262025 (Q4)0.04-0.15-0.05-183.33% (-0.10)
Nov 13, 20252025 (Q3)-0.02-0.02-0.1990.48% (+0.17)
Aug 14, 20252025 (Q2)-0.03-0.10-0.1845.00% (+0.08)
May 13, 20252025 (Q1)-0.08-0.040.37-109.76% (-0.41)
Mar 10, 20252024 (Q4)-0.12-0.05-0.0940.00% (+0.04)
Nov 07, 20242024 (Q3)-0.08-0.19-0.06-200.00% (-0.13)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed